(Q81527272)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17972944%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

title

Clinically relevant end points and new drug approvals for myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17972944%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17972944%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

author name string

K C Anderson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17972944%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

R A Kyle

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17972944%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

A K Stewart

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17972944%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

D Weber

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17972944%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

P Richardson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17972944%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

ASH/FDA Panel on Clinical Endpoints in Multiple Myeloma

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17972944%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

publication date

1 November 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17972944%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17972944%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17972944%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

231-239

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17972944%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17972944%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.leu.2405016

9 January 2020

exact match

0 references

cites work

Development of effective new treatments for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

A strategic framework for novel drug development in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Erratum: International uniform response criteria for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Prevalence of monoclonal gammopathy of undetermined significance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

A prognostic index for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

1 reference

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Impact of complete remission with intensive therapy in patients with responsive multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Single versus double autologous stem-cell transplantation for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Clinical course of patients with relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Approval summary for bortezomib for injection in the treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405016

7 January 2021